Molecular Pathways

PI(3)King Apart PTEN’s Role in Cancer

Siyuan Zhang and Dihua Yu †

Affiliations of authors: Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX.

† Correspondence to: Dihua Yu, M.D., Ph.D., Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 (e-mail: dyu@mdanderson.org); Telephone: 713-792-3636, Fax: 713-792-4454.

Running title: PTEN deficiency and cancer
Abstract

The tumor suppressor phosphatase and tensin homolog (PTEN) is a non-redundant phosphatase counteracting one of the most critical cancer promoting pathways: the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway. In addition to the canonical function of dephosphorylation of phosphatidylinositol-3,4,5-trisphosphate (PIP3), recent studies demonstrated the intriguing roles of PTEN in regulating genomic instability, DNA repair, stem cell self-renewal, cellular senescence and cell migration/metastasis. Clinically, PTEN mutations and deficiencies are prevalent in many types of human cancers. Severe PTEN deficiency is also associated with advanced stage of tumors and therapeutic resistance, such as the resistance to trastuzumab, an anti-HER2 therapy. Currently, targeting the deregulated PI3K/PTEN-Akt signaling axis has emerged as one of the major tenets in anti-cancer drug development. In this review, we will highlight our current knowledge of PTEN function and the recent discoveries in dissecting the PTEN signaling pathway. The deregulations of PTEN in cancers, the clinical lessons, and new prospects of rationally designed PI3K/Akt targeted therapy for effective cancer treatment will also be discussed.
Background

The tumor suppressor phosphatase and tensin homolog (PTEN), also known as mutated in multiple advanced cancer 1 (MMAC1), was discovered independently by two groups in 1997 (1-2). The PTEN gene is located at chromosome 10q23.31. Loss of heterozygosity (LOH) at 10q23 occurs frequently in many advanced stage sporadic tumors, e.g., approximately 70% in glioblastomas and 60% in advanced prostate cancers (2). Somatic mutations of PTEN have been identified as a prevalent event in many types of tumors, particularly those of the endometrium, brain, skin, and prostate (3). Moreover, Cowden disease patients harboring germline PTEN gene mutations have a propensity to develop breast, thyroid and skin tumors (4). As its name suggests, the PTEN protein sequence is largely homologous to protein phosphatases and a chicken cytoskeletal protein, tensin. Human PTEN protein contains 403 amino acids (Fig. 1A). The crystal structure of PTEN revealed 2 major functional domains (a phosphatase domain and a C2 domain) and 3 structural regions (a short N-terminal PIP2 binding domain, C-terminal tail containing PEST sequences followed with a PDZ interaction motif) (5). The tumor suppressor function of PTEN is disrupted by two naturally occurring mutations on its phosphatase domain: a C124S mutation that abrogates both lipid and protein phosphatase activity and a G129E mutation that abrogates only lipid phosphatase but maintains protein phosphatase activity (4). Although the N-terminal phosphatase domain is principally responsible for PTEN’s physiological activity, approximately 40% of PTEN tumorigenic mutations occur on the C-terminal C2 domain and the tail sequence, suggesting an important role of the C-terminal in maintaining PTEN function (6). A number of studies have shown that the C-terminal sequence is critical for maintaining PTEN protein stability (7).

Early studies indicated that PTEN is a dual-specificity protein phosphatase with activity towards highly acidic substrates. PTEN dephosphorylates phosphorylated serine, threonine, and tyrosine residues in peptide substrates in vitro (8) and protein substrate such as FAK (9), and the eukaryotic translation initiation factor 2 (eIF2)(10). Additionally, PTEN also auto-dephosphorylates itself by its protein phosphatase activity (11). Soon after PTEN was discovered, it was demonstrated that PTEN possesses a potent phosphatase activity for the lipid signaling second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), a lipid product of phosphatidylinositol-3-kinase (PI3K)(12). PTEN hydrolyzes the 3’phosphate on PIP3 to generate phosphatidylinositol-4,5-bisphosphate (PIP2), thereby directly antagonizing the PI3K function via abrogation of PIP3-mediated activation of downstream signaling events, including PDK1 and Akt/mTOR. The lipid phosphatase activity of PTEN is the best-
characterized physiological function contributing to the tumor suppressor function of PTEN. As no other redundant/compensatory family members have been found, PTEN is the only known lipid phosphatase counteracting the PI3K pathway. It is not surprising that loss of PTEN has a substantial impact on multiple aspects of cancer development.

Besides genetic mutations, the PTEN expression level can be regulated through multiple mechanisms including transcriptional/post-transcriptional regulations, protein-protein interactions/posttranslational modifications, and alterations of sub-cellular localization (Fig. 1B). Because of its important physiological functions, PTEN is constitutively expressed in normal tissues. A number of factors have been shown to transcriptionally regulate PTEN mRNA, including transforming growth factor β (TGFβ) (13), early growth regulated transcription factor 1 (EGR1) (14), insulin-like growth factor 2 (IGF-2) (15), peroxisome proliferation-activated receptor γ (PPARγ)(16), and p53 (17). More intriguingly, there is a complex cross-talk between PTEN and other pathways, including the RAS-MAPK pathway. The MEK-JNK pathway suppresses PTEN transcription via activation of NF-κB which directly binds to and suppresses the PTEN promoter (18), while PTEN opposes JNK signaling independent of Akt inhibition (19). PTEN mRNA is also post-transcriptionally regulated by PTEN-targeting microRNAs (miRs). For example, miR-21 regulates PTEN gene expression in human hepatocellular cancer (20) and miR-221 and -222 target PTEN, contributing to TRAIL resistance (21). Recently, intronic miR-106b~25 cluster has been demonstrated to be another PTEN-targeting microRNA locus in prostate cancer (22).

As mentioned above, numerous reports have demonstrated PTEN interaction with other proteins and post-translational modification of PTEN at C-terminal domains are the major mechanisms regulating PTEN protein stability, which has been extensively reviewed elsewhere [see review ref (23)]. In its inactive state, PTEN is phosphorylated on a cluster of serine and threonine residues located on its C-terminal tail, including Thr366, Ser370, Ser380, Thr382, Thr383, and Ser385 residues. The phosphorylation leads to a “closed” state of PTEN and maintains PTEN stability. As PTEN is being activated, dephosphorylation of its C-terminal tail opens its phosphatase domain, thereby increasing PTEN activity. Meanwhile, the open state of PTEN is more susceptible to ubiquitin-mediated proteasomal degradation (24). NEDD4-1 is a recently identified E3 ligase of PTEN, which mediates PTEN mono- and polyubiquitination (25). A number of PTEN-interacting proteins have been shown to regulate PTEN level and activities. Phosphatidylinositol 3,4,5-trisphosphate RAC exchanger 2a (P-REX2a) is a PTEN-interacting protein identified recently. Through direct binding to PTEN, P-REX2a
inhibits PTEN lipid phosphatase activity and activates the PI3K pathway (26). Tyrosine kinase Rak, a putative tumor suppressor, physically interacts with PTEN and phosphorylates PTEN on Tyr336, thereby protecting PTEN from interaction with E3 ligase NEDD4-1 and subsequent degradation (27).

The functionality of PTEN is also regulated by sub-cellular localization. PTEN interacts with a number of membrane-anchored proteins, e.g., MAGI, PAR-3, NHERF, via its C-terminal PDZ domain and dephosphorylation of PIP3 is facilitated through PTEN membrane recruitment (23). PTEN mono-ubiquitination controls PTEN nuclear entry (25). The promyelocytic leukaemia protein (PML)-herpes-virus-associated ubiquitin-specific protease (HAUSP, also known as USP7) network controls PTEN de-ubiquitination and PTEN nuclear exclusion (28).

The non-redundant PIP3 lipid phosphatase activity makes PTEN one of the most important tumor suppressors. Upon PTEN loss, excessive accumulation of PIP3 at the plasma membrane recruits and activates Akt family members, potently driving cell proliferation, apoptosis resistance, angiogenesis, and metabolism machinery through phosphorylation and activation of Akt’s downstream signaling proteins, namely mTOR, GSK3, FOXO, BAD, p27, etc. (29). PTEN mutations and hetero- or homozygous deletions are common phenomena in many types of human cancers, and have been reviewed extensively [See reviews ref (3, 30-31)].

In addition to the readily apparent role of PTEN in regulating PI3K/Akt-driven tumor progression, PTEN also plays other critical roles in multiple aspects of cancer development (Fig. 1B): 1) Genomic instability: The recent study on the nuclear function of PTEN revealed an intriguing function of PTEN in maintaining genomic stability. PTEN was found to be physically associated with centromeres. Disruption of PTEN leads to extensive centromere breakage and chromosomal translocations (32). Loss of PTEN triggers Akt-mediated cytoplasmic sequestration of cell cycle regulator CHK1 via phosphorylation and ubiquitination. Consequently, disrupted G2/S cell cycle promotes genomic instability and accumulation of DNA double strand breaks in tumor cells (33-34). Consistently, PTEN-null cells exhibit spontaneous DNA double-strand breaks (DSBs) and nuclear exclusion of PTEN has been associated with cancer progression (28). Clinically, PTEN loss is a common event in breast cancers bearing DSB repair gene BRCA1 deficiency (35). 2) Stem cell self-renewal: PTEN has essential roles in lineage fate determination of hematopoietic stem cells (HSCs). In leukemia, PTEN loss promotes self-renewable leukaemia stem cells and leukaemogenesis, while leads to HSC depletion via a cell-autonomous mechanism (36-37). mTOR has been demonstrated to be the key mediator of this process which implies a clinical application of mTOR inhibitor Rapamycin in treatment of leukaemia-
initiating cells (38). Moreover, PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry (39). p53 and PTEN cooperate in the regulation of normal and cancer stem/progenitor cell differentiation, self-renewal and tumorigenic potential (40). 3) **Cellular senescence:** a surprising finding from a gene knockout study demonstrated acute and complete inactivation of PTEN triggers growth arrest through the p53-dependent cellular senescence pathway *in vitro* and *in vivo* (41). p53-dependent cellular senescence provides a favorable selection for cells that maintain PTEN levels. Further studies demonstrated that interactions between PTEN and p53 is context-dependent. PTEN can regulate p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. PTEN loss leads to inactivation of p53 in embryonic stem (ES) cells and brain tissues (42). However, others reported that PTEN loss activates p53 in prostate tumor and colorectal cancer cell lines (41, 43).

4) **Cell migration and metastasis:** PTEN negatively regulates intracellular levels of PIP3 in cells, which is critical for chemoattractant gradient sensing (44). PTEN accumulates at a contralateral sub-cellular side of the migration leading edge and is required for proper chemotaxis (45). Although PTEN controls cell migration, the exact role of PTEN in tumor invasion and metastasis is still elusive. 5) **Tumor microenvironment:** a significant role of PTEN in regulating tumor microenvironment has been recently reported. Genetic knockout of *PTEN* in fibroblasts of mouse mammary gland tumors creates a tumor-permissive stroma, which accelerates the initiation, progression, and malignant transformation of mammary epithelial tumors (46).

**Clinical-Translational Advances**

**Targeting PI3K/Akt to overcome PTEN functional loss**

The receptor tyrosine kinase (RTK)/PI3K/Akt pathway is one the most potent driving forces promoting tumor progression. The major consequences of PTEN mutations and deficiencies are PI3K/Akt pathway hyperactivation. Because of the substantial role the hyperactivated PI3K pathway plays in cancer development, targeting PI3K signaling is one of the most concentrated areas of anti-cancer drug development. More than one hundred lead compounds targeting multiple nodes of PI3K signaling, including PI3K, Akt, mTOR, etc., are in the pre-clinical drug development pipeline. A great number of promising agents have entered intensive Phase I/II/III clinical investigations. At the time of writing this review, there are a total of 195 clinical trials ongoing for PI3K pathway-targeting agents in various cancer types, including 33 trials for PI3K inhibitors, 68 trials for Akt inhibitors, and 95 trials for mTOR inhibitors (**www.ClinicalTrials.gov**). Rapamycin and it analogs, which inhibit the mTOR
complex, are the clinically most advanced agents. Temsirolimus (CCI-779, Wyeth Pharmaceuticals) was approved by US Food and Drug Administration (US FDA) in 2007 for treatment of advanced renal-cell carcinoma.

Although PI3K signaling is an obvious target for cancer therapy, given the redundancy and complex feedback regulation existing in the PI3K pathway, the clinical efficacy of many PI3K pathway inhibitors is modest, which largely hinders the clinical usage of PI3K inhibitors as single agents. There are huge challenges facing us that require more in-depth understanding of the pathway. Firstly, emerging evidence has indicated that different PI3K isoforms, besides generally believed functional redundancy, have their own distinct roles in cancer development. Collectively, recent studies have suggested that PTEN-null tumors are more dependent on PI3K isoform p110β but not p110α (47), and are thereby sensitive to p110β inhibitors (48). On the other hand, PTEN-loss tumors harboring gain-of-function PIK3CA mutations (e.g. H1047R and E545K) seem to be more dependent on p110α. Because of this complexity, isoform-specific inhibitors and personalized treatment are clearly warranted in the clinic.

With the recent advances in dual- or multi-specific targeting drug design, novel agents such as NVP-BEZ235, which targets mutation-specific forms of PI3K as well as mTOR, have delivered an exciting and promising pre-clinical efficacy in treatment for tumors bearing gain-of-function PIK3CA mutations (49). Secondly, it has been well-noted that there are extensive feedback loops and cross-talks between the signaling networks driving tumor progression. The mTOR downstream protein p70S6K is a negative regulator of PI3K signaling through inhibition of Insulin Receptor Substrate 1 (IRS1) signaling. Inhibition of mTOR could release this inhibition and trigger a positive feedback to reactivate PI3K signaling (50). A recent study also suggested an additional cross-talk between the PI3K pathway and RAS mediated MAPK pathway. Blockade of PI3K signaling may shift the tumor survival signaling to a RAS-MAPK dependent manner (51). With the above notion in mind, the next generation dual-specific inhibitors or clinical trials of novel combinatorial therapy targeting both PI3K signaling and MAPK signaling are highly expected to counteract the signaling cross-talk and maximize the efficacy of anti-PI3K pathway inhibitors.

Additionally, PI3K signaling inhibitors may be used effectively to overcome the resistance to anti-RTK therapies and chemotherapies. PTEN is the key antagonist of the PI3K/Akt pathway. Loss of PTEN in many types of cancer has been shown to correlate not only with the tumor development but also with clinical resistance to many anti-cancer drugs, especially targeted therapies for the RTK pathway. In breast cancer, the anti-HER2/ErbB2 antibody, trastuzumab, represents one of the most
successful examples of rationally designed targeted therapy in treatment of cancer. However, in the clinic, 30% of patients show de novo resistance to trastuzumab (52). Our group first demonstrated that PTEN loss in breast tumors confers significant trastuzumab resistance (53). This concept has been further validated in a different patient cohort showing hyper-activation of the PI3K/Akt axis as a result of PTEN loss and PIK3CA gain-of-function mutation (H1047R and E545K) led to a worse patient response to trastuzumab (54). Similarly, hyper-activation of PI3K/Akt also has been associated with a poor sensitivity to anti-EGFR therapies (cetuximab and gefitinib) in colon and lung cancer patients (55-56). Although the efficacy of the dual HER2 and EGFR inhibitor, lapatinib, seems to be independent of PTEN status (57), the overall lapatinib response is still largely affected by the activity of PI3K pathway (58). In addition, PTEN loss leads to up-regulation of anti-apoptotic protein expression, e.g. Bcl-2 and FLIPs, which render resistance to traditional chemotherapy and apoptosis-inducing agent TRAIL (21, 59). To overcome the resistance of anti-RTK therapy, the current theme of rationally designed combinatorial therapy favors combination of anti-RTK drugs, e.g. trastuzumab, with inhibitors targeting the compensatory signaling pathway, e.g. PI3K. For example, our pre-clinical studies showed that the combination of trastuzumab with either Akt-inhibitor or mTOR inhibitor are effective in overcoming PTEN-loss-induced trastuzumab resistance (60). Currently, multiple trials of trastuzumab in combination with either a PI3K inhibitor (e.g. XL147, Exelixis) or mTOR inhibitor (e.g. RAD001, Novartis) are under clinical evaluation. Similarly, clinical trials combining a PI3K pathway inhibitor with current first line anti-EGFR therapy are designed for better treatment of EGFR-driven tumors. These trials include XL147 plus erlotinib in treatment of Non-Small Cell Lung Cancer (NSCLC) and RAD001 plus Cetuximab/gefitinib in treatment of metastatic pancreatic cancer prostate cancer, among others (www.ClinicalTrials.gov).

Clearly, more basic and pre-clinical mechanistic studies are needed to further elucidate the complexity of the cancer signaling pathway networks. Evolution of our knowledge on the PI3K/PTEN pathway will guide us to design more powerful weapons to fight cancer.
**Acknowledgements**

The authors would like to thank Mr. Frank J. Lowry and Yu lab members for valuable comments on this manuscript. Dr. S. Zhang is a Susan G. Komen Breast Cancer Foundation Postdoctoral Fellowship awardee (KG091316). Dr. D. Yu is the Hubert L. & Olive Stringer Distinguished Chair in Basic Science at M. D. Anderson Cancer Center.

**Note**

We apologize for not being able to cite all the relevant original research and review articles due to space limitation.
References


Figure legend

Fig. 1 PTEN pathway and regulation. A) PTEN protein structure. PTEN protein contains: a N-terminal PIP2 binding motif, a phosphatase domain, a C2 domain, a C-terminal tail containing PEST sequences and a PDZ interaction motif at the end (5). Two naturally occurring mutations on the phosphatase domain disrupt PTEN’s phosphatase activity: C124S mutation which abrogates both lipid and protein phosphatase activity and G129E mutation which abrogates only lipid phosphatase but not protein phosphatase activity. B) PTEN is regulated at different levels. 1) PTEN mRNA transcription is activated by EGR1, IGF2, PPARγ, p53 etc. and inhibited by MEK-mediated NF-κB activation. 2) PTEN mRNA is also post-transcriptional regulated by PTEN targeting miRNAs, including miR21, miR221/222 and miR25. PTEN protein is extensively regulated by post-translational modifications. 3) Protein stability is primarily regulated by phosphorylation of C-terminal tail domains (Thr366, Ser370, Ser380, Thr382, Thr383, and Ser385). The phosphorylation leads to a “close” state of PTEN and maintains PTEN stability. Dephosphorylation C-terminal tail opens PTEN phosphatase domain, thereby increases PTEN activity. 4) NEDD4-1 is an E3 ligase of PTEN, which mediates PTEN ploy and mono-ubiquitination. Poly-ubiquitin leads to proteasomal degradation of PTEN. Mono-ubiquitination of PTEN promotes its nuclear translocation. 5) Ubiquitin-specific protease HAUSP de-ubiquitinates PTEN In the nucleus, and leads to PTEN nuclear exclusion. PTEN biological function includes membrane function and nuclear function. 6) On cell membrane, PTEN dephosphorylates PIP3 and consequently suppresses PI3K pathway. 7) PTEN also regulates cell cycle through Akt-mediated cytoplasmic sequestration of cell cycle regulator CHK1. 8) PTEN physically associates with centromeres in the nucleus and maintains chromosome stability.
Clinical Cancer Research

PI(3)King Apart PTEN's Role in Cancer

Siyuan Zhang and Dihua Yu

Clin Cancer Res  Published OnlineFirst July 8, 2010.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-09-2990

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.